IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	(Jointly Administered)

AMENDED SCHEDULES OF ASSETS AND LIABILITIES FOR MARLINSPIKE THERAPEUTICS, INC. CASE NO. 25-12203

Amended Herein:

- Supplemental Schedule G: Executory Contracts and Unexpired Leases

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Squar Incorporated (8493). The location of the Debtors' service address in thes New York, NY 10169.

25121772607010000000000017

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	Case No. 25-12177 (LSS)
Debtors.	(Jointly Administered)

SUPPLEMENTAL GLOBAL NOTES REGARDING
THE DEBTORS' AMENDED SCHEDULES OF ASSETS AND LIABILITIES

On January 30, March 4, and March 5, 2026, Apple Tree Life Sciences, Inc. ("ATLS"), and its debtor affiliates, as debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the "Debtors"), filed their respective *Schedules of Assets and Liabilities* (each, a "Schedule," and collectively, the "Schedules") and *Statements of Financial Affairs* (each, a "Statement," and collectively with the Schedules, the "Schedules and Statements") with the United States Bankruptcy Court for District of Delaware (the "Bankruptcy Court") pursuant to section 521 of title 11 of the United States Code (the "Bankruptcy Code"), rule 1007 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), and Rule 1007-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the "Local Rules"). The Schedules and Statements are filed at Docket Nos. 236-242, 429-436, 439-442 & 446-447.

The Debtors are filing these amendments to the Schedules (the "Supplemental Schedules") in accordance with the Bankruptcy Code, Bankruptcy Rules, and Local Rules. These Supplemental Schedules are in addition to, and are not in replacement of, any portion of the Schedules. Any consideration of these Supplemental Schedules should be done in tandem with review of the Schedules and Statements previously filed, including any global notes attached thereto.

These global notes and statements of limitations, methodology and disclaimers regarding the Debtors' Supplemental Schedules (the "Supplemental Global Notes") pertain to, are incorporated by reference in, and comprise an integral part of, all of the Supplemental Schedules and should be referred to, and referenced in connection with, any review of the Supplemental Schedules.[2] Similarly, the global notes affixed to the Debtors' Schedules and Statements (the

[1] The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

[2] These Supplemental Global Notes supplement, and are in addition to, any specific notes contained in each Debtor's Supplemental Schedules. The fact that the Debtors prepared these Supplemental Global Notes with respect to any of the individual Debtor's Supplemental Schedules and not to those of another should not be

"Global Notes") pertain to, are incorporated by reference in, and comprise an integral part of the Supplemental Schedules. The Global Notes should be reviewed in connection with any review of these Supplemental Global Notes and the Supplemental Schedules.

Schedule E/F: Creditors Who Have Unsecured Claims

The liabilities identified in Supplemental Schedule E/F, Part 2, are derived from the Debtors' books and records. The Debtors made reasonable attempts to set forth their unsecured obligations, although the actual amount of claims against the Debtors may vary from those liabilities represented on Supplemental Schedule E/F, Part 2. The listed liabilities may not reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims. The amounts listed on Supplemental Schedule E/F may not reflect any right of setoff or recoupment, and the Debtors reserve any such setoff or recoupment rights. Some of the scheduled liabilities may be unknown, contingent and/or unliquidated at this time. In such cases, the amounts may be listed as "Undetermined." Accordingly, the Supplemental Schedules, in connection with the Schedules and Statements, may not equal the aggregate value of the Debtors' total liabilities as noted on any previously issued financial statements.

In addition to nonpriority unsecured claims by third-party claimants, intercompany payables between and among the Debtors and non-Debtor affiliates may also be reported on Supplemental Schedule E/F, Part 2. The intercompany claims/listing of payments to affiliates are for general services and the payment for/of services under pre-existing agreements.

Schedule G: Unexpired Leases and Executory Contracts

The contracts, agreements and leases listed on Supplemental Schedule G may have expired or may have been modified, amended or supplemented from time to time by various amendments, restatements, waivers, estoppels, certificates, letters, memoranda or other documents, instruments and agreements that may not be listed on Supplemental Schedule G, despite the Debtor's use of reasonable efforts to identify such documents. Certain of the executory contracts and unexpired leases listed on Supplemental Schedule G may contain certain renewal options, guarantees of payment, options to purchase, rights of first refusal, and other miscellaneous rights, which are not set forth separately on Supplemental Schedule G. In addition, the Debtor may have entered into various other types of agreements in the ordinary course of business, such as subordination, non disturbance and attornment agreements, supplemental agreements, amendments/letter agreements, title agreements and confidentiality agreements. Such documents may not be set forth on Supplemental Schedule G. Certain of the executory contracts may not have been memorialized and may be subject to dispute. Certain of the executory contracts or unexpired leases listed in Supplemental Schedule G may include one or more ancillary documents, including but not limited to any underlying assignment and assumption agreements, amendments, supplements, full and partial assignments, renewals and

---

interpreted as a decision by the Debtors to exclude the applicability of such Supplemental Global Note to any of the Debtors' Supplemental Schedules, as appropriate.

partial releases. Executory contracts that are oral in nature, if any, have not been included on Supplemental Schedule G. To the extent the Bankruptcy Court determines a particular contract is executory, the Debtor will amend the Schedules to add that contract, as necessary or appropriate.

Omission of a contract or agreement from Supplemental Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. The Debtor's rights under the Bankruptcy Code with respect to any such omitted contracts or agreements are not impaired by the omission.

Fill in this information to identify the case:

Debtor Name: In re : Marlinspike Therapeutics, Inc.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12203 ()

☑ Check if this is an amended filing

Official Form 206G

Schedule G: Executory Contracts and Unexpired Leases 12/15

Be as complete and accurate as possible. If more space is needed, copy and attach the additional page, numbering the entries consecutively.

1. **Does the debtor have any executory contracts or unexpired leases?**
   - ☐ No. Check this box and file this form with the court with the debtor's other schedules. There is nothing else to report on this form.
   - ☑ Yes. Fill in all of the information below even if the contracts or leases are listed on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B).

2. **List all contracts and unexpired leases**	**State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease**
2.1 **State what the contract or lease is for and the nature of the debtor's interest**: Stock Purchase Agreement	ATP Life Science Ventures, L.P. Name
	Notice Name
State the term remaining: N/A	230 Park Avenue Address
	Suite 2800
List the contract number of any government contract	New York (City) / NY (State) / 10169 (ZIP Code)
	Country

Fill in this information to identify the case:

Debtor Name: In re : Marlinspike Therapeutics, Inc.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12203 ()

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to $500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☐ *Schedule A/B: Assets–Real and Personal Property* (Official Form 206A/B)
- ☐ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☐ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☐ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☐ *Schedule H: Codebtors* (Official Form 206H)
- ☐ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☑ Amended *Schedule* Supplemental Schedule G - Executory Contracts and Unexpired Leases
- ☐ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders (Official Form 204)*
- ☐ Other document that requires a declaration

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 07/01/2026
MM / DD / YYYY

✖ / s / Perry M. Mandarino
Signature of individual signing on behalf of debtor

Perry M. Mandarino
Printed name

Chief Restructuring Officer
Position or relationship to debtor